Precigen (PGEN) director Randal Kirk discloses multi-day share sales
Rhea-AI Filing Summary
Precigen, Inc. (PGEN) reported insider activity by director and 10% owner Randal J. Kirk on a Form 4. Through entity Kapital Joe, he sold 1,086,153 shares of common stock on 11/19/2025 at a weighted average price of $4.47, 942,832 shares on 11/20/2025 at a weighted average price of $4.08, and 937,308 shares on 11/21/2025 at $3.83.
The filing notes that the first two prices are weighted averages for multiple trades within reported price ranges, and Kirk undertakes to provide full trade details on request. After these sales, he continues to report large indirect beneficial ownership positions in Precigen through multiple entities, including 7,434,384 shares held by Kapital Joe and 82,164,767 shares held by R.J. Kirk Declaration of Trust, along with additional holdings through various family and investment vehicles.
Positive
- None.
Negative
- None.
Insights
Large insider sales by a 10% owner/director reduce direct exposure but leave substantial indirect holdings outstanding.
The filing shows that **Randal J. Kirk**, a **director** and **10% owner** of **Precigen, Inc. (PGEN)**, reported three open‑market sales of common stock on
Beyond Kapital Joe, the filing lists large additional indirect holdings in multiple entities, including **82,164,767** shares via **R.J. Kirk DOT** and multi‑million share positions in several other LLCs and partnerships, plus 6,085,471 shares via **Third Security, LLC** and 1,144,481 shares held by his spouse. All of these may be deemed beneficially owned under Rule 13d‑3, although he disclaims beneficial ownership except to the extent of any pecuniary interest. This means his economic exposure remains very significant even after the reported sales.
The concrete takeaway is a noticeable reduction in one indirect position, not an exit: a total of 2,966,293 shares were sold over three days, while aggregate indirect positions across entities remain large. The sales were executed over price ranges disclosed in the footnotes, and the weighted‑average disclosure suggests many small trades within those bands. A key item to watch over the next few quarters is whether similar Form 4 filings show continued net selling from these entities or a stable remaining stake.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 937,308 | $3.83 | $3.59M |
| Sale | Common Stock | 942,832 | $4.08 | $3.85M |
| Sale | Common Stock | 1,086,153 | $4.47 | $4.86M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.31 to $4.68, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.90 to $4.42, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Randal J. Kirk controls each of Kapital Joe, LLC ("Kapital Joe"), R.J. Kirk Declaration of Trust ("R.J. Kirk DOT"), Parkview 2020 Limited Partnership ("Parkview 2020"), JPK 2008 LLC ("JPK 2008"), JPK 2009 LLC ("JPK 2009"), JPK 2012 LLC ("JPK 2012"), MGK 2008 LLC ("MGK 2008"), MGK 2009 LLC ("MGK 2009"), MGK 2011 LLC ("MGK 2011"), ZSK 2008 LLC ("ZSK 2008"), ZSK 2009 LLC ("ZSK 2009"), Kellie L. Banks (2009) Long Term Trust ("Kellie L. Banks LTT"), Lotus Capital (2000) Company, Inc. ("Lotus"), Sunset 2020 LLC ("Sunset 2020") and Third Security, LLC ("Third Security"). Shares held by these entities may be deemed to be beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
FAQ
What insider transaction did PGEN report for Randal J. Kirk?
The Form 4 shows that Randal J. Kirk, a director and 10% owner of Precigen, Inc. (PGEN), reported sales of common stock on 11/19/2025, 11/20/2025, and 11/21/2025 through the entity Kapital Joe.